Literature DB >> 6265689

[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].

J Pausch, A Holstege, D Keppler, W Gerok.   

Abstract

1. An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs. This treatment provides a somewhat extended survival but no cure. 2. The treatment of hepatocellular carcinoma in patients by reduction of an inactive precursor of a cytocidal alkylating agent by azoreductase of the tumor showed no therapeutic effect. 3. A selective hepatocellular uptake of drugs coupled to asialoglycoproteins has been described. An application of this concept for the chemotherapy of hepatocellular carcinoma seems doubtful since a loss of binding proteins for desialylated glycoproteins during experimental hepatocarcinogenesis has been demonstrated. 4. The increased uptake of 5-fluorouridine in hepatomas after induction of a tissue-specific depletion of uridine 5'-triphosphate and cytidine 5'-triphosphate provides an effective experimental chemotherapy with limited side effects. A clinical use of this new concept for the chemotherapy of hepatocellular carcinoma may serve as a useful approach.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265689     DOI: 10.1007/BF02593848

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  46 in total

1.  CB 10-252 in the treatment of primary hepatocellular carcinoma.

Authors:  I M Murray-Lyon; M H Tattersall; H Thomas; S Sherlock; M Cochrane; R Williams; A E Read
Journal:  Med Chir Dig       Date:  1978

2.  THE MODE OF ACTION OF 5-FLUOROURACIL AND ITS DERIVATIVES.

Authors:  S S Cohen; J G Flaks; H D Barner; M R Loeb; J Lichtenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1958-10-15       Impact factor: 11.205

3.  [Liver tumors caused by environmental factors].

Authors:  H Popper
Journal:  Internist (Berl)       Date:  1977-04       Impact factor: 0.743

4.  The clinical pharmacology of a hepatoma-specific alkylating agent.

Authors:  C A Curt; T A Cannors; I M Murray-Lyon; M H Tattersall
Journal:  Biochem Pharmacol       Date:  1977-09-15       Impact factor: 5.858

5.  Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.

Authors:  L H Baker; J H Saiki; S E Jones; J S Hewlett; R W Brownlee; R L Stephens; V K Vaitkevicius
Journal:  Cancer Treat Rep       Date:  1977-11

6.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

7.  Cytotoxic agents designed to be selective for liver cancer.

Authors:  A Bukhari; T A Connors; A M Gilsenan; W C Ross; M J Tisdale; G P Warwick; D E Wilman
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

8.  Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.

Authors:  T Anukarahanonta; A Holstege; D O Keppler
Journal:  Eur J Cancer       Date:  1980-09       Impact factor: 9.162

9.  Biochemical strategy of the genome as expressed in regulation of pyrimidine metabolism.

Authors:  G Weber; T Shiotani; H Kizaki; D Tzeng; J C Williams; N Gladstone
Journal:  Adv Enzyme Regul       Date:  1977 Oct 3-4

10.  Uridine kinase activity in human tumors.

Authors:  M Otal-Brun; T E Webb
Journal:  Cancer Lett       Date:  1979-01       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.